Open AccessA phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations
Author(s) -
Jordi Rodón,
Pauline Funchain,
Theodore W. Laetsch,
HendrikTobias Arkenau,
Alice Hervieu,
Christian F. Singer,
Yonina R. MurcianoGoroff,
Sant P. Chawla,
Kristin Anthony,
Ikuo Yamamiya,
Mei Liu,
Abdel Halim,
Karim A. Benhadji,
Osamu Takahashi,
Suzette Delaloge
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0305
Subject(s) - pten , cowden syndrome , pi3k/akt/mtor pathway , medicine , cancer research , germline , germline mutation , tolerability , protein kinase b , cancer , mutation , biology , signal transduction , gene , genetics , adverse effect